Related Experiment Videos
Nucleotide sequence of HLA-B*5505, which expresses a unique HLA class I polymorphism
S Szmania1, K Seurynck, L A Baxter-Lowe
1University of South Carolina, Center for Cancer Treatment and Research, Columbia 29203, USA.
Tissue Antigens
|May 1, 1997
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Should HLA mismatch acceptability for sensitized transplant candidates be determined at the high-resolution rather than the antigen level?
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2015
Center-defined unacceptable HLA antigens facilitate transplants for sensitized patients in a multi-center kidney exchange program.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2014
Dynamic challenges inhibiting optimal adoption of kidney paired donation: findings of a consensus conference.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2013
Questionable expression of unstable DQ heterodimer containing HLA-DQA1*01:07.
Tissue antigens·2015
Lung biopsy strategies for childhood interstitial lung disease: Indications and techniques.
The Journal of international medical research·2026
"I know how important it is": A qualitative analysis of participants' experiences in a vaccine safety study.
Human vaccines & immunotherapeutics·2026
Evolution and Mechanistic Insights of Immunometabolism in Metabolic Diseases and Infections.
Scandinavian journal of immunology·2026
Early longitudinal proteomic changes during sirolimus therapy in tocilizumab-refractory idiopathic multicentric Castleman disease.
Rheumatology (Oxford, England)·2026
Pharmacokinetic and pharmacodynamic sub-study of trans-arterial vs. intravenous gemcitabine in the TIGeR-PaC phase 3 clinical trial.
Cancer chemotherapy and pharmacology·2026